会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 48. 发明公开
    • 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
    • 用于预防或治疗非酒精性脂肪肝疾病的药物组合物
    • KR1020130103190A
    • 2013-09-23
    • KR1020120024632
    • 2012-03-09
    • 한미사이언스 주식회사
    • 임세영박성희신령애최인영권세창
    • A61K38/17A61K38/16A61P1/16
    • A61K47/48215A61K38/26A61K39/3955A61K47/60A61K47/6883A61K2039/505C07K14/605C07K16/18C07K2317/41C07K2317/75C07K2317/94A61K38/17A61K38/16A61K38/28
    • PURPOSE: A pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease (NAFLD) is provided to prevent accumulation of triglyceride, thereby basically preventing and treating NAFLD. CONSTITUTION: A pharmaceutical composition for preventing or treating NAFLD contains an insulinotropic peptide drug conjugate in which insulinotropic peptides are conjugated with an immunoglobulin Fc region through a non-peptidyl polymer. The insulinotropic peptides are selected among exendin-4, an exendin-4 derivative in which an N-terminal amine group of exendin-4 is removed, an exendin-4 derivative in which the N-terminal amine group of exendin-4 is substituted with a hydroxyl group, an exendin-4 derivative in which the N-terminal amine group of exendin-4 is modified with a dimethyl group, and an exendin-4 derivative in which alpha carbon of an N-terminal histidine residue and alpha carbon-conjugated N-terminal amine group are removed. The non-peptidyl polymer is selected among polyethylene glycol, polypropylene glycol, an ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid, and a combination thereof.
    • 目的:提供一种预防或治疗非酒精性脂肪性肝病(NAFLD)的药物组合物,以防止甘油三酯的积累,从而基本上预防和治疗NAFLD。 构成:用于预防或治疗NAFLD的药物组合物含有促胰岛素肽药物缀合物,其中促胰岛素肽通过非肽基聚合物与免疫球蛋白Fc区缀合。 促胰岛素肽选自毒蜥外泌肽-4,其中除去毒蜥外泌肽-4的N-末端胺基的毒蜥外泌肽-4衍生物,毒蜥外泌肽-4的N-末端胺基取代的毒蜥外泌肽-4衍生物 羟基,毒蜥外泌肽-4的N-末端胺基用二甲基修饰的毒蜥外泌肽-4衍生物,以及毒蜥外泌肽-4衍生物,其中N-末端组氨酸残基的α碳和α碳共轭的 去除N-末端胺基。 非肽基聚合物选自聚乙二醇,聚丙二醇,乙二醇 - 丙二醇共聚物,聚氧乙烯化多元醇,聚乙烯醇,多糖,葡聚糖,聚乙烯基乙醚,生物可降解聚合物,脂质聚合物,壳多糖,透明质酸和组合 它们。
    • 50. 发明公开
    • 생리활성 폴리펩타이드 결합체 제조 방법
    • 生物活性多肽共聚物的制备方法
    • KR1020130049671A
    • 2013-05-14
    • KR1020110114828
    • 2011-11-04
    • 한미사이언스 주식회사
    • 김대진장명현김승수이종수최재혁권세창
    • C07K17/10C07K17/08C07K1/18
    • C07K14/62A61K47/60C07K1/1077C07K17/08C07K2319/30C07K2319/31C07K17/10C07K1/18
    • PURPOSE: A method for preparing a physiologically active polypeptide conjugate is provided to highly maintain activity in vivo, to remarkably increase a half life in blood, and to enhance drug compliance. CONSTITUTION: A method for preparing a physiologically active polypeptide and non-polypeptide polymer connector comprises: a step of reacting a physiologically active polypeptide and a non-polypeptide polymer in a reaction solution containing an organic solvent; and a step of isolating and purifying the physiologically active polypeptide connector from the reacted mixture. The organic solvent is C1-C10 alcohol. The alcohol is selected from the group consisting of isopropanol, ethanol, and methanol. The reaction solution contains 10-60wt% of organic solvent. [Reference numerals] (AA) Insulin beta chain; (BB) Insulin alpha chain; (CC) PEG_insulin beta chain
    • 目的:提供一种制备生理活性多肽缀合物的方法,以高度保持体内的活性,显着增加血液中的半衰期,并提高药物依从性。 构成:制备生理活性多肽和非多肽聚合物连接体的方法包括:使生理活性多肽和非多肽聚合物在含有机溶剂的反应溶液中反应的步骤; 以及从反应混合物中分离和纯化生理活性多肽连接体的步骤。 有机溶剂为C1-C10醇。 醇选自异丙醇,乙醇和甲醇。 反应溶液含有10-60重量%的有机溶剂。 (AA)胰岛素β链; (BB)胰岛素α链; (CC)PEG胰岛素β链